News

Trump Executive Order Could Reshape How Americans Pay for Drugs. Why It Isn’t Bad for Pharma Stocks.
The Trump administration’s Monday executive order could restructure how Americans buy prescription drugs, pushing them away ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
CVS opts for Wegovy over Zepbound, affecting drug access for some
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...
Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs — 2nd Update
U.S. trade policy has also heightened investor concerns over the potential impact to Novo Nordisk's key market. U.S. President Trump has threatened to unveil tariffs on pharmaceutical products in the ...